A randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of MK-0677 [ibutamoren] 25 mg in the treatment of primary fibromyalgia

Trial Profile

A randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of MK-0677 [ibutamoren] 25 mg in the treatment of primary fibromyalgia

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2012

At a glance

  • Drugs Ibutamoren (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2012 Additional lead trial investigator (Bennett R) added as reported by ClinicalTrials.gov record.
    • 02 Sep 2010 Results were reproted at the 13th World Congress on Pain.
    • 02 Sep 2010 Primary endpoint 'Fibromyalgia Impact Questionnaire' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top